100
Participants
Start Date
May 6, 2014
Primary Completion Date
August 1, 2024
Study Completion Date
August 1, 2024
5-Fluorouracil
400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours, Day 1 and Day 15 .
Leucovorin
200-400 mg/m2 IV over 2 hours, Day 1 and Day 15
Irinotecan
IV infusion over 90 minutes, dosed at 180, 260 or 310 mg/m2 based on genotype.
Bevacizumab
Bevacizumab (5 mg/kg IV infused as per institutional policy, IV, Day 1, 15)
Bon Secours Cancer Institute, Midlothian
Cone Health Cancer Center, Greensboro
University of North Carolina, Chapel Hill
Rex Healthcare, Raleigh
Carolina Healthcare Systems, Charlotte
IU Simon Cancer Center, Indianapolis
IU Arnett Hospital, Lafayette
University Cancer Research Fund
UNKNOWN
UNC Lineberger Comprehensive Cancer Center
OTHER